The U.S. Supreme Court ruling last week allowing companies to challenge patents while under license may increase lawsuit frequency and force biotechnology companies to tread carefully when applying for patents, but is less likely to affect research or funding, according to biotech experts."I don't think this [ruling] is a major impediment" to research in the biotech industry, Robert Nicholas, a biotech patent attorney at McDermott Will and Emory, told The Scientist. "People are going to continue to invest in areas that have a lot of biomedical promise."The 8-1 ruling found that MedImmune could continue its lawsuit against Genentech over the validity of Genentech's patent on Cabilly II, a process involving the production of human antibodies. MedImmune obtained a license for Cabilly I in 1997, which it uses to make Synagis, a drug that prevents lower respiratory tract disease in children and accounted for approximately 80 percent of the company's...
The ScientistAssociation of University Technology ManagersThe ScientistRonald EisensteinThe Scientistthousands of biotech patentsThe Scientist firstname.lastname@example.org http://www.supremecourtus.gov/opinions/06pdf/05-608.pdfhttp://www.autm.net/index.cfmThe Scientisthttp://www.the-scientist.com/article/display/24479http://www.bio.org/speeches/pubs/er/statistics.asp
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!